Fundamental Analysis of INOVIO PHARMACEUTICALS INC(NASDAQ:INO) stock

Fundamental Rating

Overall INO gets a fundamental rating of 2 out of 10. We evaluated INO against 568 industry peers in the Biotechnology industry. INO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INO is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year INO has reported negative net income.

In the past year INO has reported a negative cash flow from operations.

INO had negative earnings in each of the past 5 years.

In the past 5 years INO always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -105.43%, INO is doing worse than 77.52% of the companies in the same industry.

INO's Return On Equity of -153.49% is on the low side compared to the rest of the industry. INO is outperformed by 64.42% of its industry peers.

		Industry Rank	Sector Rank
ROA	-105.43%
ROE	-153.49%
ROIC	N/A

ROA(3y)-73.52%

ROA(5y)-66.86%

ROE(3y)-105.65%

ROE(5y)-765.57%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for INO has been increased compared to 1 year ago.

The number of shares outstanding for INO has been increased compared to 5 years ago.

The debt/assets ratio for INO is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -24.38, we must say that INO is in the distress zone and has some risk of bankruptcy.

INO's Altman-Z score of -24.38 is on the low side compared to the rest of the industry. INO is outperformed by 89.38% of its industry peers.

INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-24.38

ROIC/WACCN/A

WACC11.56%

2.3 Liquidity

INO has a Current Ratio of 3.88. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of INO (3.88) is comparable to the rest of the industry.

INO has a Quick Ratio of 3.88. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 3.88, INO perfoms like the industry average, outperforming 47.96% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.88
Quick Ratio	3.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

INO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.34%, which is quite impressive.

INO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -76.14%.

Measured over the past years, INO shows a very negative growth in Revenue. The Revenue has been decreasing by -51.34% on average per year.

EPS 1Y (TTM)40.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%42.95%

Revenue 1Y (TTM)-76.14%

Revenue growth 3Y-51.76%

Revenue growth 5Y-51.34%

Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 13.55% on average over the next years. This is quite good.

INO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 166.24% yearly.

EPS Next Y25.93%

EPS Next 2Y19.94%

EPS Next 3Y17.69%

EPS Next 5Y13.55%

Revenue Next Year-76.33%

Revenue Next 2Y-58.82%

Revenue Next 3Y135.27%

Revenue Next 5Y166.24%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year INO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

INO's earnings are expected to grow with 17.69% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.94%

EPS Next 3Y17.69%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

INO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (12/18/2024, 11:27:41 AM)

1.8973

-0.06 (-3.2%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap49.52M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-105.43%
ROE	-153.49%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.88
Quick Ratio	3.88
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)40.34%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y25.93%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-76.14%

Revenue growth 3Y-51.76%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

INOVIO PHARMACEUTICALS INC (INO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens